Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a Healthcare company (Biotechnology) with a market capitalization of $487M. The Maz Rating grades it against the other companies in its sector.
Capricor Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.41, Capricor Therapeutics, Inc. trades at 2.4x book value, with an EV/EBITDA of 0.5. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -56.7%, return on invested capital of -50.8% and a free cash flow yield of -29.5%. On the balance sheet: a debt-to-equity ratio of 0.44 and a current ratio of 6.77. Over the past 52 weeks the share price ranged from $2.96 to $40.37, with a beta of 0.53.
Capricor Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 9 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.